Boston Scientific Corp (BSX)vsCeriBell, Inc (CBLL)
BSX
Boston Scientific Corp
$48.55
-0.34%
HEALTHCARE · Cap: $70.87B
CBLL
CeriBell, Inc
$18.25
-2.67%
HEALTHCARE · Cap: $651.86M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 21584% more annual revenue ($20.61B vs $95.07M). BSX leads profitability with a 17.3% profit margin vs -63.5%. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
CBLL
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.4%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Intrinsic value data unavailable for CBLL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Conservative balance sheet, low leverage
Revenue surging 29.3% year-over-year
Areas to Watch
No major concerns identified
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -42.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : CBLL
The strongest argument for CBLL centers on Debt/Equity, Revenue Growth. Revenue growth of 29.3% demonstrates continued momentum.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : CBLL
The primary concerns for CBLL are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
BSX profiles as a mature stock while CBLL is a growth play — different risk/reward profiles.
CBLL is growing revenue faster at 29.3% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BSX scores higher overall (76/100 vs 31/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
CeriBell, Inc
HEALTHCARE · MEDICAL DEVICES · USA
CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company is headquartered in Sunnyvale, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?